December 5, 2025Indian Journal of DermatologyOpen Access

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo

View Full Paper

Ask AI

Bookmark

Authors

SJSoumya JagadeesanAmrita Institute of Medical Sciences and Research Centre NPNithisha PrasadNew Mexico State University PDPrasanna DuraiswamyChristian Medical College, Vellore

Discussion

Member takes

Implication

Retrospective analysis shows significant efficacy of tofacitinib treatment in non-segmental vitiligo patients, indicating potential benefits over conventional therapies.

Key Points

Mean VASI scores improved significantly from 5.038 to 1.269 at 24 weeks, suggesting effective treatment.
Eighty-one percent of patients achieved over 50% improvement, reflecting strong positive outcomes.
Observational review coupled oral tofacitinib with topical tacrolimus and phototherapy for enhancing skin pigmentation.
Transient leukopenia occurred in three patients, while one developed palmar warts, highlighting the need for monitoring.

Cite This Study

Jagadeesan et al. (2025) studied this question.

synapsesocial.com/papers/694023c82d562116f28fca36 https://doi.org/10.4103/ijd.ijd_141_25

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows significant efficacy of tofacitinib treatment in non-segmental vitiligo patients, indicating potential benefits over conventional therapies.

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider